Stickler syndrome, type 4
diseaseOn this page
Also known as autosomal recessive Stickler syndrome caused by mutation in COL9A1COL9A1 autosomal recessive Stickler syndromeSTICKLER syndrome, type IVSTL4
Summary
Stickler syndrome, type 4 (MONDO:0013590) is a disease caused by COL9A1 (GenCC Definitive), with 2 cohort genes.
At a glance
- Causal gene: COL9A1 (GenCC Definitive)
- Cohort genes: 2
- ClinVar variants: 38
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Stickler syndrome, type 4 |
| Mondo ID | MONDO:0013590 |
| OMIM | 614134 |
| UMLS | C3279941 |
| MedGen | 481571 |
| GARD | 0018358 |
| Is cancer (heuristic) | no |
Also known as: autosomal recessive Stickler syndrome caused by mutation in COL9A1 · COL9A1 autosomal recessive Stickler syndrome · STICKLER syndrome, type IV · STL4
Data availability: 38 ClinVar variants · 5 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by body system or component › syndromic disease › Stickler syndrome › Stickler syndrome, type 4
Related subtypes (4): Stickler syndrome type 1, Stickler syndrome type 2, Stickler syndrome, type 5, Stickler syndrome, type 6
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
38 retrieved; paginated sample, class counts are floors:
24 uncertain significance, 6 conflicting classifications of pathogenicity, 2 benign/likely benign, 2 pathogenic, 2 likely pathogenic, 1 likely benign, 1 pathogenic/likely pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 1388848 | NM_001851.6(COL9A1):c.14G>A (p.Trp5Ter) | COL9A1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 161449 | NM_001851.6(COL9A1):c.1519C>T (p.Arg507Ter) | COL9A1 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 17195 | NM_001851.6(COL9A1):c.883C>T (p.Arg295Ter) | COL9A1 | Pathogenic | criteria provided, single submitter |
| 2664714 | NM_001851.6(COL9A1):c.1450-1G>T | COL9A1 | Likely pathogenic | criteria provided, single submitter |
| 597109 | NM_001851.6(COL9A1):c.1052C>A (p.Ser351Ter) | COL9A1 | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 282983 | NM_001851.6(COL9A1):c.1634G>A (p.Arg545His) | COL9A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 357811 | NM_001851.6(COL9A1):c.902C>T (p.Pro301Leu) | COL9A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 374336 | NM_001851.6(COL9A1):c.876+2T>A | COL9A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 449774 | NM_001851.6(COL9A1):c.353G>A (p.Arg118Gln) | COL9A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 833926 | NM_001851.6(COL9A1):c.460G>C (p.Val154Leu) | COL9A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 930660 | NM_001851.6(COL9A1):c.352C>T (p.Arg118Ter) | COL9A1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 547841 | NM_001844.5(COL2A1):c.2618G>T (p.Gly873Val) | COL2A1 | Uncertain significance | criteria provided, single submitter |
| 1054519 | NM_001851.6(COL9A1):c.680C>T (p.Pro227Leu) | COL9A1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1064099 | NM_001851.6(COL9A1):c.2404G>A (p.Gly802Ser) | COL9A1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1318479 | NM_001851.6(COL9A1):c.2228C>T (p.Ala743Val) | COL9A1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1354895 | NM_001851.6(COL9A1):c.73G>C (p.Val25Leu) | COL9A1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1381175 | NM_001851.6(COL9A1):c.2270C>T (p.Pro757Leu) | COL9A1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1386321 | NM_001851.6(COL9A1):c.1561G>C (p.Ala521Pro) | COL9A1 | Uncertain significance | criteria provided, single submitter |
| 1420675 | NM_001851.6(COL9A1):c.2333C>T (p.Ala778Val) | COL9A1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1464634 | NM_001851.6(COL9A1):c.2158C>T (p.Arg720Trp) | COL9A1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1493374 | NM_001851.6(COL9A1):c.2552A>G (p.Asn851Ser) | COL9A1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1699500 | NM_001851.6(COL9A1):c.2284A>G (p.Ile762Val) | COL9A1 | Uncertain significance | criteria provided, single submitter |
| 17194 | NM_001851.6(COL9A1):c.876+2dup | COL9A1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1805759 | NM_001851.6(COL9A1):c.2260G>C (p.Gly754Arg) | COL9A1 | Uncertain significance | criteria provided, single submitter |
| 2664842 | NM_001851.6(COL9A1):c.1864G>A (p.Gly622Arg) | COL9A1 | Uncertain significance | criteria provided, single submitter |
| 2664923 | NM_001851.6(COL9A1):c.443G>A (p.Gly148Asp) | COL9A1 | Uncertain significance | criteria provided, single submitter |
| 3393168 | NM_001851.6(COL9A1):c.1558-10C>T | COL9A1 | Uncertain significance | criteria provided, single submitter |
| 357800 | NM_001851.6(COL9A1):c.2617C>G (p.Arg873Gly) | COL9A1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 3594101 | NM_001851.6(COL9A1):c.2708C>A (p.Pro903Gln) | COL9A1 | Uncertain significance | criteria provided, single submitter |
| 393272 | NM_001851.6(COL9A1):c.1553A>T (p.Asp518Val) | COL9A1 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 10 · Orphanet: 20 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| COL9A1 | Definitive | Autosomal recessive | Stickler syndrome, type 4 | 10 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| COL9A1 | Orphanet:166002 | Multiple epiphyseal dysplasia due to collagen 9 anomaly |
| COL9A1 | Orphanet:250984 | Autosomal recessive Stickler syndrome |
| COL2A1 | Orphanet:137678 | Spondyloepiphyseal dysplasia with metatarsal shortening |
| COL2A1 | Orphanet:166100 | Autosomal dominant otospondylomegaepiphyseal dysplasia |
| COL2A1 | Orphanet:1856 | Spondyloperipheral dysplasia-short ulna syndrome |
| COL2A1 | Orphanet:209867 | Autosomal dominant rhegmatogenous retinal detachment |
| COL2A1 | Orphanet:2380 | Legg-Calvé-Perthes disease |
| COL2A1 | Orphanet:459051 | Spondyloepiphyseal dysplasia, Stanescu type |
| COL2A1 | Orphanet:485 | Kniest dysplasia |
| COL2A1 | Orphanet:85166 | Platyspondylic dysplasia, Torrance type |
| COL2A1 | Orphanet:85198 | Dysspondyloenchondromatosis |
| COL2A1 | Orphanet:86820 | Familial avascular necrosis of femoral head |
| COL2A1 | Orphanet:90653 | Stickler syndrome type 1 |
| COL2A1 | Orphanet:93279 | Mild spondyloepiphyseal dysplasia due to COL2A1 mutation with early-onset osteoarthritis |
| COL2A1 | Orphanet:93296 | Achondrogenesis type 2 |
| COL2A1 | Orphanet:93297 | Hypochondrogenesis |
| COL2A1 | Orphanet:93315 | Spondylometaphyseal dysplasia, ‘corner fracture’ type |
| COL2A1 | Orphanet:93316 | Spondylometaphyseal dysplasia, Schmidt type |
| COL2A1 | Orphanet:93346 | Spondyloepimetaphyseal dysplasia congenita, Strudwick type |
| COL2A1 | Orphanet:94068 | Spondyloepiphyseal dysplasia congenita |
Cohort genes → proteins
2 cohort genes, 2 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 2 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| COL9A1 | HGNC:2217 | ENSG00000112280 | P20849 | Collagen alpha-1(IX) chain | gencc,clinvar |
| COL2A1 | HGNC:2200 | ENSG00000139219 | P02458 | Collagen alpha-1(II) chain | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| COL9A1 | Collagen alpha-1(IX) chain | Structural component of hyaline cartilage and vitreous of the eye. |
| COL2A1 | Collagen alpha-1(II) chain | Type II collagen is specific for cartilaginous tissues. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 2 | 1.8× | 0.312 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| COL9A1 | Other/Unknown | no | Collagen, ConA-like_dom_sf, TSPN-like_N | |
| COL2A1 | Other/Unknown | no | Fib_collagen_C, VWF_dom, Collagen |
Expression context
Cohort genes with no expression data: 0.
2 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 2 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| cartilage tissue | 2 |
| tibia | 2 |
| ventricular zone | 1 |
| corpus epididymis | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| COL9A1 | 149 | broad | marker | tibia, cartilage tissue, ventricular zone |
| COL2A1 | 145 | broad | marker | tibia, cartilage tissue, corpus epididymis |
Protein interactions among cohort
Intra-cohort edges: 1.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| COL2A1 | 2,491 |
| COL9A1 | 1,488 |
Intra-cohort edges
| A | B | Sources |
|---|---|---|
| COL2A1 | COL9A1 | biogrid_interaction, intact, string_interaction |
Structural data
PDB: 2 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| COL2A1 | P02458 | 11 |
| COL9A1 | P20849 | 5 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 13. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Collagen chain trimerization | 2 | 259.6× | 7e-05 | COL9A1, COL2A1 |
| Signaling by PDGF | 2 | 253.8× | 7e-05 | COL9A1, COL2A1 |
| NCAM1 interactions | 2 | 248.3× | 7e-05 | COL9A1, COL2A1 |
| Assembly of collagen fibrils and other multimeric structures | 2 | 200.3× | 7e-05 | COL9A1, COL2A1 |
| Collagen degradation | 2 | 175.7× | 7e-05 | COL9A1, COL2A1 |
| Collagen biosynthesis and modifying enzymes | 2 | 170.4× | 7e-05 | COL9A1, COL2A1 |
| ECM proteoglycans | 2 | 150.3× | 8e-05 | COL9A1, COL2A1 |
| Integrin cell surface interactions | 2 | 134.3× | 9e-05 | COL9A1, COL2A1 |
| Fibronectin matrix formation | 1 | 285.5× | 0.005 | COL2A1 |
| MET activates PTK2 signaling | 1 | 190.3× | 0.007 | COL2A1 |
| Developmental Lineage of Pancreatic Ductal Cells | 1 | 114.2× | 0.010 | COL2A1 |
| Non-integrin membrane-ECM interactions | 1 | 77.2× | 0.014 | COL2A1 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 1 | 43.6× | 0.023 | COL2A1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| otic vesicle development | 1 | 1404.3× | 0.005 | COL2A1 |
| anterior head development | 1 | 1404.3× | 0.005 | COL2A1 |
| cartilage development involved in endochondral bone morphogenesis | 1 | 1203.7× | 0.005 | COL2A1 |
| proteoglycan metabolic process | 1 | 936.2× | 0.005 | COL2A1 |
| notochord development | 1 | 842.6× | 0.005 | COL2A1 |
| limb bud formation | 1 | 766.0× | 0.005 | COL2A1 |
| embryonic skeletal joint morphogenesis | 1 | 766.0× | 0.005 | COL2A1 |
| cartilage condensation | 1 | 383.0× | 0.008 | COL2A1 |
| tissue homeostasis | 1 | 280.9× | 0.008 | COL2A1 |
| cellular response to BMP stimulus | 1 | 280.9× | 0.008 | COL2A1 |
| endochondral ossification | 1 | 271.8× | 0.008 | COL2A1 |
| extrinsic apoptotic signaling pathway in absence of ligand | 1 | 234.1× | 0.009 | COL2A1 |
| negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 1 | 205.5× | 0.009 | COL2A1 |
| heart morphogenesis | 1 | 187.2× | 0.010 | COL2A1 |
| chondrocyte differentiation | 1 | 150.5× | 0.010 | COL2A1 |
| inner ear morphogenesis | 1 | 150.5× | 0.010 | COL2A1 |
| cartilage development | 1 | 125.8× | 0.011 | COL2A1 |
| roof of mouth development | 1 | 123.9× | 0.011 | COL2A1 |
| collagen fibril organization | 1 | 112.3× | 0.012 | COL2A1 |
| animal organ morphogenesis | 1 | 95.8× | 0.013 | COL9A1 |
| skeletal system development | 1 | 62.9× | 0.019 | COL2A1 |
| central nervous system development | 1 | 57.7× | 0.020 | COL2A1 |
| sensory perception of sound | 1 | 50.5× | 0.021 | COL2A1 |
| regulation of gene expression | 1 | 41.7× | 0.025 | COL2A1 |
| visual perception | 1 | 39.8× | 0.025 | COL2A1 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2
Druggability breadth: 1 of 2 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| COL9A1 | 0 | 0 |
| COL2A1 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| COL2A1 | 2 | Binding:2 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 2 | COL9A1, COL2A1 |
Undrugged target profiles
2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| COL9A1 | 0 | — |
| COL2A1 | 2 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.